# Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects

> **NCT01887366** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 208 (actual)

## Conditions studied

- Cocaine Addiction

## Interventions

- **DRUG:** TV-1380 150 mg
- **DRUG:** TV-1380 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01887366
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01887366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01887366, "Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01887366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*